ISSN: 1837-9664Journal of Cancer
Global reach, higher impact
J Cancer 2017; 8(6):1018-1024. doi:10.7150/jca.17358 This issue Cite
Research Paper
IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma
1. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea;
2. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
3. Department of Internal Medicine, Keimyung University Dongsan Medical Center, Daegu, Korea.
Citation:
Heo MH, Park HY, Ko YH, Kim WS, Kim SJ. IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. J Cancer 2017; 8(6):1018-1024. doi:10.7150/jca.17358. https://www.jcancer.org/v08p1018.htm
Other stylesAbstract
Background: Interferon regulatory factor 4 (IRF4)/multiple myeloma oncogene-1 (MUM1) is a member of the interferon regulatory factor family of transcriptional factors. Although IRF4/MUM1 expression is associated with aggressiveness of B-cell lymphoma and multiple myeloma, the prognostic value of IRF4/MUM1 expression in peripheral T-cell lymphoma (PTCL) is unclear.
Methods: We analyzed a tissue array from 69 patients diagnosed with PTCL. The expression levels of IRF4/MUM1 and associated proteins such as MYC and Ikaros were analyzed by immunohistochemistry. Samples were classified by IRF4/MUM1 expression into a negative group (less than 5% of all tumor cells staining positive) or a positive group (≥ 5% of all tumor cells staining positive).
Results: IRF4/MUM1 expression was observed in 33% of all patients (23/69), most frequently in patients with anaplastic large cell lymphoma (ALCL, 78%, 7/9). Patients with PTCL, not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) showed expression rates of 33% (9/28) and 50% (4/8), respectively, whereas only 3 patients with extranodal NK/T-cell lymphoma (12%, 3/24) showed positive staining. The percentage of IRF4-positive tumor cells was significantly associated with the percentage of MYC-positive tumor cells (R: 0.410, P=0.013). Comparison of survival outcomes revealed that the IRF4/MUM1-positive group exhibited worse survival than the IRF4/MUM1-negative group; moreover, IRF4/MUM1-positive patients with a high level of MYC expression had the worst survival of all patients with nodal PTCL (PTCL-NOS, AITL, and ALCL; n=45) (P < 0.05).
Conclusions: IRF4/MUM1 expression was associated with poor survival outcomes in PTCL, implying that this gene is a potential therapeutic target.
Keywords: IRF4, MUM1, PTCL
Citation styles
APA
Heo, M.H., Park, H.Y., Ko, Y.H., Kim, W.S., Kim, S.J. (2017). IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. Journal of Cancer, 8(6), 1018-1024. https://doi.org/10.7150/jca.17358.
ACS
Heo, M.H.; Park, H.Y.; Ko, Y.H.; Kim, W.S.; Kim, S.J. IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. J. Cancer 2017, 8 (6), 1018-1024. DOI: 10.7150/jca.17358.
NLM
Heo MH, Park HY, Ko YH, Kim WS, Kim SJ. IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. J Cancer 2017; 8(6):1018-1024. doi:10.7150/jca.17358. https://www.jcancer.org/v08p1018.htm
CSE
Heo MH, Park HY, Ko YH, Kim WS, Kim SJ. 2017. IRF4/MUM1 expression is associated with poor survival outcomes in patients with peripheral T-cell lymphoma. J Cancer. 8(6):1018-1024.
This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.